Research progress of lncRNA and chemotherapy resistance in colorectal cancer

doi:10.12092/j.issn.1009-2501.2018.04.016

Abstract

Abstract:

Colorectal cancer (CRC) is a common gastrointestinal tumor with high incidence and mortality rates. Chemotherapy is the basic treatment for colorectal cancer, but chemoresistance is one of the most important causes of therapy failure in CRC, and the mechanism is not yet fully understood. Long noncoding RNA (lncRNA) represents a class of RNA transcripts longer than 200 nucleotides with no protein coding potential which could involve in cancer occurrence and development by the regulation of chromatin remodeling, transcription, and posttranscriptional processing. Recently, emerging evidences indicate that lncRNAs play an important role in the development and maintenance of chemoresistance. Different lncRNAs have been shown to confer chemoresistance in cancer cells by changing multiple drug resistance (MDR) transporters, modulating the cellular apoptosis rate, affecting the epithelial mesenchymal transition (EMT) process, and modulating signaling pathways. In this review, we discuss the mechanism of lncRNAs in drug resistance of colorectal cancer and provide a theoretical evidence for solving the problem of drug resistance in colorectal cancer.

Key words: colorectal cancer, lncRNA, chemotherapy, resistance mechanisms

CLC Number:

R735.3+5

HU Yang, LI Zhixing, WANG Guo, ZHU Yuanshan. Research progress of lncRNA and chemotherapy resistance in colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 456-463.

References

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132.
［2］Rebecca L,Siegel MPH, Kimberly D, et al. Colorectal cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(3):177-193.
［3］Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy［J］. Biochem Pharmacol, 2013, 85(9): 1219-1226.
［4］Li H, Ma SQ, Huang J, et al. Roles of long noncoding RNAs in colorectal cancer metastasis.［J］. Oncotarget, 2017, 8(24): 39859-39876.
［5］Luo J, Qu J, Wu DK, et al. Long non-coding RNAs: a rising biotarget in colorectal cancer［J］. Oncotarget, 2017, 8(13): 22187-22202.
［6］Martinezbalibrea E, Martínezcardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance［J］. Mol Cancer Ther, 2015, 14(8): 1767-1776.
［7］Zhang N, Yin Y, Xu SJ, et al 5-Fluorouracil: mechanisms of resistance and reversal strategies［J］. Molecules, 2008,13(8): 1551-1569.
［8］Petitprez A, Larsen AK. Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models［J］. Curr Pharm Des, 2013, 19(5):958.
［9］Xu Y, Villalonacalero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity［J］. Ann Oncol, 2002, 13(12):1841-1851.
［10］Alexander RP, Fang G, Rozowsky J, et al. Annotating noncoding regions of the genome［J］. Nat Rev Genet, 2010, 11(8):559-571.
［11］Ma L, Baji VB, Zhang Z. On the classification of long non-coding RNAs［J］. RNA Biol, 2013, 10(6): 924-933.
［12］Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs［J］. Mol Cell, 2011, 43(6): 904-914.
［13］Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer［J］. Biochim Biophys Acta, 2014, 1839(11): 1097-1109.
［14］Wu R, Su Y, Wu H, et al. Characters, functions and clinical perspectives of long non-coding RNAs［J］. Mol Genet Genomics, 2016, 291(3): 1013-1033.
［15］孙跃胜, 屈强, 潘江华,等. 长链非编码RNA在结直肠癌中的作用［J］. 中国临床药理学与治疗学, 2017, 22(2): 222-227.
［16］Ma Y, Yang Y, Wang F, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/βcatenin signalling pathway via suppression of activator protein 2α［J］. Gut, 2016, 65(9):1494.
［17］Qiao L, Liu X, Tang Y, et al. Knockdown of long noncoding RNA prostate cancer-associated ncRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells［J］. Mol Cell Biochem, 2018,441(1/2): 99-108.
［18］Li L, Shang J, Zhang Y, et al. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatininduced cell apoptosis［J］. Oncol Rep, 2017, 38(3): 1383-1392.
［19］Shen Y, Liu SS, Fan J, et al. Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions［J］. EMBO Rep, 2017, 18(4): 536-548.
［20］Li P, Zhang X, Wang H, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2［J］. Mol Cancer Ther, 2017, 16(4): 739-751.
［21］Li Y, Huang S, Li Y, et al. Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells［J］. Tumour Biol, 2016, 37(10): 14205-14215.
［22］Bian Z, Jin L, Zhang J, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p［J］. Sci Rep, 2016, 6:23892.
［23］Gao H, Song X, Kang T, et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer［J］. Onco Targets Ther, 2017, 10:205.
［24］Han P, Li JW, Zhang BM, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling［J］. Mol Cancer, 2017, 16(1):9.
［25］Li C, Gao Y, Li Y, et al. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis［J］. Biochem Biophys Res Commun, 2017, 491(2):552-557.
［26］Yue B, Cai D, Liu C, et al. Linc00152 Functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer［J］. Mol Ther, 2016, 24(12):2064-2077.
［27］Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer［J］. Oncotarget,2015,6(26):22513.
［28］Li J, Li X, Cen C, et al. The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31［J］. Oncol Rep, 2018,39(1):217-226.
［29］Li P, Zhang X, Wang L, et al. lncRNA HOTAIR contributes to 5FU resistance through suppressing miR-218 and activating NFκB/TS signaling in colorectal cancer［J］. Mol Ther Nucleic Acids, 2017, 8:356.
［30］Yang X, Yurievich UA, Yosypovych SV. Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5fluorouracilinduced cell cytotoxicity through promoting thymidylate synthase expression［J］. Oncotarget, 2017, 8(47):83171-83182.
［31］Wu KF, Liang WC, Feng L, et al. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/βcatenin pathway［J］. Exp Cell Res, 2017, 350(2):312-317.
［32］Lee H, Kim C, Ku JL, et al. A long non-coding RNA snaR contributes to 5-Fluorouracil resistance in human colon cancer cells［J］. Mol Cells, 2014, 37(7):540-546.
［33］Xiong W, Jiang YX, Ai YQ, et al. Microarray analysis of long non-coding RNA expression profile associated with 5fluorouracilbased chemoradiation resistance in colorectal cancer cells［J］. Asian Pac J Cancer Prev,2017, 16(8):3395-3402.
［34］Sun QL, Zhao CP, Wang TY, et al. Expression profile analysis of long non-coding RNA associated with vincristine resistance in colon cancer cells by next-generation sequencing［J］. Gene, 2015, 572(1):79.
［35］Cui H, Zhang AJ, Chen M, et al. ABC Transporter inhibitors in reversing multidrug resistance to chemotherapy［J］. Curr Drug Targets, 2015, 16(12):1356-1371.
［36］Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, Pglycoprotein)［J］. Pharmacogenet Genomics, 2011, 21(3):152-161.
［37］Zhu QN, Wang G, Guo Y, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4AMDR1 pathway［J］. Oncotarget, 2017, 8(54):91990-92003.
［38］Takashi T, Mikihiko N, Akihiro T, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal［J］. Cancer Sci, 2003, 94(1):15-21.
［39］Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy［J］. Oncogene, 2007, 26(9):1324-1337.
［40］Radisky DC. Epithelial-mesenchymal transition ［J］. J Cell Sci,2005,118(Pt 19):4325-4326.
［41］Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics［J］. Cancer Gene Ther, 2012, 19(11):723-730.
［42］Bayoumi AS, Sayed A, Broskova Z, et al. Crosstalk between long noncoding RNAs and microRNAs in health and disease［J］. Int J Mol Sci, 2016, 17(3):356.
［43］Qu J, Min L, Wen Z, et al. Competing endogenous RNA in cancer: a new pattern of gene expression regulation［J］. Int J Clin Exp Med, 2015, 8(10):17110.
［44］Malin W, Cecilia D, Jelena M, et al. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance［J］. Nat Commun, 2015, 6:8904.
［45］胡明珠,李佩玲.非编码RNA在卵巢癌中的研究进展［J］.疑难病杂志,2016,15(11):1197-1200,1205.
［46］Lavie O, Edelman D, Levy T, et al. A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19DTA) in subjects with recurrent ovarian/peritoneal cancer.［J］. Arch Gynecol Obstet, 2017, 295(3):751-761.

[1]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[4]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[5]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[6]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[7]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[8]	WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru. Applications of BGUSs inhibition in tumor prevention and chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974.
[9]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[10]	ZHAO Quanfeng, FU Peishu, GU Wenrui, ZHEN Dan, LV Zongjie, YANG Yang. Advances in evidence-based medical research of GnRHa for fertility protection after chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1449-1454.
[11]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.
[12]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[13]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[14]	TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822.
[15]	ZHAO Miaohui, ZHOU Jiani, QI Yong. Mulberry polysaccharides improves the chemotherapy of liver cancer ascites tumor-bearing mice by regulating the PI3K/AKT/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 401-407.